ADCYAP1 and migraine disorder: Reports also show that intravenous administration of PACAP-38 can elicit a migraine-like attack in patients (Schytz et al., 2009) and cause sustained meningeal vasodilation and migraine-like photophobia in mice (Markovics et al., 2012).